ABBOTT LABORATORIES Business Summary

Abbott Laboratories (ABT) employs a diversified healthcare model, generating revenue through the global sale of medical devices, diagnostic systems, nutritional products, and branded generic pharmaceuticals. The company’s operations are categorized into four core segments: Medical Devices, the largest revenue contributor (~48%) driven by the FreeStyle Libre glucose monitoring system; Diagnostics, which is currently scaling its oncology portfolio through the pending 2026 acquisition of Exact Sciences; Nutrition, encompassing pediatric and adult brands like Similac and Ensure; and Established Pharmaceuticals, focused on emerging market generics. Abbott operates a transaction-based model, selling to healthcare providers, wholesalers, and retail consumers. Positioned against primary competitors Medtronic, Roche, and Johnson & Johnson, Abbott maintains a dominant market share in continuous glucose monitoring and rapid diagnostics, leveraging a "consumer-centric" technology strategy to outpace peers in organic growth. Founded in 1888 by Dr. Wallace C. Abbott, the corporation is currently led by Chairman and CEO Robert B. Ford, who has overseen a strategic shift toward digital health integration and decentralized diagnostics. The executive leadership includes Philip P. Boudreau as Executive Vice President and CFO, and Lisa D. Earnhardt, Executive Vice President and Group President of Medical Devices. The governance structure is overseen by a Board of Directors featuring prominent figures such as Nancy McKinstry (CEO of Wolters Kluwer) and Dr. Nita Ahuja, with a planned reduction to 12 members effective April 2026. As a prominent S&P 500 Dividend Aristocrat with 54 consecutive years of payout increases, Abbott is backed by major institutional investors including The Vanguard Group and BlackRock, reflecting its status as a low-volatility cornerstone in the global healthcare investment landscape.